Lung cancer screening for survivors of head and neck cancer
Head and neck cancer survivors with long smoking histories had a 2.5-fold greater risk of developing lung cancer than those without prior head and neck cancer, according to… read more.
Head and neck cancer survivors with long smoking histories had a 2.5-fold greater risk of developing lung cancer than those without prior head and neck cancer, according to… read more.
First national analysis of external-beam radiation as bridging therapy finds fewer than 4% of patients prescribed this non-invasive option. People with liver cancer awaiting transplantation could benefit from… read more.
Eli Lilly announced updated data from the positive Phase III monarchE trial evaluating the investigational use of Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for… read more.
Deciphera Pharmaceuticals, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Qinlock… read more.
Merck Inc announced that the Phase III KEYNOTE-394 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in Asian patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib met… read more.
Drugs which are already (U.S.) Food and Drug Administration (FDA) approved could be effective in treating of lung cancer in “never-smokers,” researchers reported on Sept. 30, 2021 in… read more.
BeiGene has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of BRUKINSA (zanubrutinib)… read more.
In fruit flies, antioxidants reverse tumor-related cardiac dysfunction. Ohio State University A new study in animal models shows that the presence of a cancer tumor alone can lead… read more.
Ground-breaking Phase III head-to-head DESTINY-Breast03 results featured at ESMO Presidential Symposium support Enhertu as the potential new standard of care in previously treated patients. DESTINY-Breast01 Phase II trial… read more.
Updated results from the CASPIAN Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained,… read more.
BUFFALO, N.Y. — Having second- or third-degree relatives with colorectal cancer increases a person’s risk of developing the disease, according to the findings of a study led by… read more.
Massachusetts Institute of Technology MIT engineers, in collaboration with scientists at Cancer Research UK Manchester Institute, have developed a new way to grow tiny replicas of the pancreas,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.